AMID surging measles outbreaks, pediatric cancer survivors experience steep drops in vaccine immunity following their chemotherapy. A cross-sectional clinical evaluation involving 54 pediatric oncology patients demonstrated that 79.6% lacked protective antibodies against at least one measles, mumps, and rubella component at a median of 2.5 years after completing therapy. Measles immunity was the most severely compromised, with 64.8% of survivors testing seronegative, followed by 55.6% for mumps and 35.2% for rubella. Furthermore, 42.6% of patients were seronegative for two viruses, and 16.7% lacked protective antibodies against all three pathogens, leaving only 20.4% fully protected despite prior immunization.
Chemotherapy suppresses humoral and cellular immunity by depleting circulating T and B lymphocytes, impairing memory cells responsible for durable protection against vaccine-preventable infections. Although all participants received at least one vaccine dose before diagnosis and 83.3% received two doses, systemic cytotoxic regimens dismantled preexisting defenses. Patients diagnosed with hematologic malignancies experienced particularly profound immune deficits, with only 9.7% maintaining full protection compared to 34.8% of individuals treated for solid tumors. In contrast, rubella-specific antibodies exhibited greater resilience, possibly reflecting more durable memory B-cell populations after chemotherapy.
Clinical analyses revealed that measles antibody loss correlated with specific temporal factors during survivorship. Children evaluated more than five years after completing chemotherapy showed significantly higher rates of measles seronegativity than those tested earlier, at 37.1% versus 10.5% (p=0.04). Additionally, patients who lost measles protection had received their second vaccine dose at an older age, averaging 86.4 months compared to 44.9 months among seropositive peers (p=0.002). This pattern suggests that a shorter interval between vaccination and chemotherapy initiation may impair adequate immune memory establishment before intensive therapy begins.
With community measles outbreaks creating heightened transmission hazards, unimmunized survivors face substantial risks of severe illness, pneumonia, and secondary complications. Current clinical guidelines exhibit notable discrepancies regarding post-treatment revaccination timing, with recommendations ranging from three to six months following therapy. The persistent loss of measles immunity reinforces the urgent clinical need for standardized revaccination protocols within routine childhood cancer survivorship care. In clinical settings where serologic testing is constrained, universal revaccination without prior antibody testing represents a pragmatic strategy to safeguard vulnerable pediatric populations.
Reference
Nakasuwan K et al. Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy. BMC Res Notes. 2026;19:39.
Featured Image: Joa Souza on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
